PMA Review Timelines & FDA Decision Process

The Premarket Approval (PMA) pathway applies to Class III devices that pose the highest risk or for which general and special controls are insufficient to provide reasonable assurance of safety and effectiveness. Because FDA must affirmatively find that a PMA device is safe and effective — a higher standard than 510(k) substantial equivalence — the review is more intensive and the timeline is longer.

Submission vs. Filing: The Acceptance Review

The PMA clock does not start on the day FDA receives the application. FDA first conducts an acceptance review — a 45-day administrative check to determine whether the application is complete enough to begin substantive review. If the submission is administratively incomplete, FDA issues a Refuse to Accept (RTA) decision and returns the application. Once FDA accepts the application for filing, the 180-day substantive review clock begins.

This distinction matters for planning. From submission to a final decision, the minimum elapsed calendar time for a complete, well-prepared PMA with no panel and no Additional Information requests is typically around 180 + 45 = 225 days. Most PMAs take considerably longer.

The 180-Day Substantive Review Clock

After filing, FDA has 180 days under 21 CFR Part 814 to complete its review and reach a decision. FDA assigns the application to a primary reviewer, a secondary reviewer, and typically a multidisciplinary review team covering clinical, biostatistical, engineering, and labeling aspects. CDRH tracks PMA review performance against MDUFA goals, which target substantive interaction at certain intervals.

The 180-day clock can be tolled — paused — if FDA issues a major Additional Information (AI) request. When the clock is tolled, FDA is waiting for data or analyses it needs before it can proceed. The toll ends when the applicant submits an AI response, and FDA resumes review. The statutory 180-day clock does not restart; it resumes from where it was tolled. However, each AI round adds real calendar time.

Additional Information Requests

An Additional Information request is FDA's formal mechanism for asking the applicant to supply missing data, clarify ambiguities, or provide new analyses. AI requests may cover clinical data interpretation, statistical methods, human factors study results, biocompatibility, or labeling content. A well-structured AI response addresses each item specifically, provides responsive data without reopening issues, and includes a clear executive summary.

Multiple AI rounds are possible. Experienced applicants anticipate likely reviewer concerns during preparation and address them proactively in the original submission, reducing the probability of receiving an AI request.

Advisory Panel Meetings

FDA is not required to convene an advisory panel for every PMA, but will do so for novel technologies, first-of-a-kind devices, or applications with complex benefit-risk tradeoffs. Advisory panels include independent scientific, clinical, and consumer experts who review the submission data, hear presentations from both the applicant and FDA, and vote on whether the device provides reasonable assurance of safety and effectiveness.

Panel meetings are public events and typically occur well within the 180-day review window. Panel recommendations are advisory — FDA is not bound by the vote — but departing from a panel recommendation requires explanation. Preparing effectively for an advisory panel presentation is distinct from preparing the PMA itself and is a significant undertaking.

FDA's Final Decision Options

At the conclusion of review, FDA issues one of four actions:

• Approval Order: FDA has found that the device has a reasonable assurance of safety and effectiveness and may be marketed as described in the application.
• Approvable Letter: FDA is prepared to approve the device but has identified minor outstanding items — often labeling conditions or commitments — that must be resolved before the formal approval order issues.
• Not Approvable Letter: FDA has identified significant deficiencies that the applicant must address in a complete response before FDA can approve. This is a setback but not a final denial.
• Order Denying Approval: FDA has determined that the evidence does not support a finding of reasonable assurance of safety and effectiveness. The applicant may request a hearing.

Realistic PMA Timeline Planning

Device manufacturers planning a PMA should account for acceptance review (45 days), substantive review (180 days), potential AI round(s) (60–90 days each), and, if applicable, panel preparation and meeting scheduling. A PMA with one AI round and no panel commonly takes 12–18 months from initial submission to approval. PMAs requiring panel review or multiple AI rounds routinely exceed 24 months.

Pre-submission meetings (Q-Subs) before PMA filing can reduce AI rounds by aligning FDA and the applicant on protocol design, clinical endpoints, and labeling before the study begins. Investing in a structured pre-submission program before a pivotal study is one of the most effective ways to manage PMA review time.

Frequently Asked Questions

How long does FDA have to review a PMA?

The statutory review period for a PMA is 180 days from the date FDA files the application. Filing occurs after FDA completes an acceptance review (45 days) and determines the application is sufficiently complete to begin substantive review. The 180-day clock starts at filing, not at submission. FDA may extend this clock if a major additional information request is issued, effectively resetting or tolling the review period.

What is an Additional Information (AI) request in PMA review?

During PMA review, FDA may issue an Additional Information (AI) request — formerly called a major deficiency letter — asking the applicant to provide clarifying data, additional analyses, or new testing. The clock is tolled while FDA awaits the AI response. Once the applicant submits the AI response, FDA resumes review. Multiple AI rounds are possible, each tolling the clock again. The cumulative effect can extend the actual calendar time well beyond 180 days.

When does FDA convene an advisory panel for a PMA?

FDA is not required to convene an advisory panel for every PMA, but typically does so for novel technologies, first-of-a-kind devices, or applications with complex benefit-risk profiles. The panel is composed of independent scientific and clinical experts who review the data and vote on whether the device has a reasonable assurance of safety and effectiveness. Panel meetings are public and add several months to the overall timeline.

What are the possible final FDA decisions on a PMA?

FDA can issue one of four decisions on a PMA: (1) Approval — device may be marketed as submitted; (2) Approvable letter — FDA is prepared to approve pending specific conditions or minor changes; (3) Not Approvable letter — significant deficiencies exist that must be addressed before approval is possible; (4) Denial — FDA has determined the device does not meet the statutory standard. An Approvable or Not Approvable letter triggers an applicant response cycle.